The research, led by Hyman B. Muss of the University of North Carolina at Chapel Hill and Mina S. Sedrak of UCLA, together with colleagues at City of Hope and the Mayo Clinic, examined 251 women with early-stage breast cancer and 49 cancer-free controls. The team measured p16INK4a, a gene whose expression rises as cells enter senescence—a state of permanent growth arrest linked to aging and disease—and compared it against five DNA methylation clocks: Horvath, Hannum, PhenoAge, GrimAge, and the Dunedin Pace of Aging, known as mPoA. DNA methylation clocks estimate biological age from characteristic patterns of chemical tags on DNA that shift predictably over a lifetime.

The two biomarker families barely spoke to each other. Across both cancer patients and controls, correlations between T-cell p16 and the methylation clocks were weak, with correlation coefficients generally below 0.3. In the cancer cohort, p16 showed only modest associations with Hannum, PhenoAge, and GrimAge, and none at all with the Horvath clock or the Dunedin pace measure. The pattern held in the control group and in a separate cohort of younger patients, where the strongest relationship—between p16 and GrimAge—reached only a moderate correlation of 0.40. The Dunedin measure, which estimates the rate of aging rather than accumulated age, showed essentially no relationship with p16 anywhere.

That disconnect matters because researchers and clinicians increasingly rely on these tests to gauge whether diseases or treatments are accelerating aging, and to evaluate interventions meant to slow it down. If p16 and methylation clocks captured the same underlying biology, they could be used interchangeably. The new findings suggest they cannot. The authors argue that the two measures reflect fundamentally different aspects of aging: p16 tracks senescence within a specific immune cell population, while methylation clocks integrate epigenetic signals across the heterogeneous mixture of cell types found in whole blood. Differences in biological compartment, measurement scale, and clock design—all calibrated differently, some to chronological age and others to mortality risk—likely all contribute to the weak overlap.

The study also probed whether cancer itself leaves a measurable imprint on these markers. When the researchers plotted biomarker levels against chronological age, women with breast cancer did not differ from controls in p16, Hannum, Horvath, or the Dunedin pace measure. But two of the mortality-informed clocks told a different story: GrimAge and PhenoAge were both significantly higher in the cancer group, and the differences persisted after adjusting for race, ethnicity, and body mass index. The result aligns with a growing body of evidence that cancer is associated with physiological changes consistent with accelerated aging, while suggesting that standard epigenetic clocks are not uniformly sensitive to that signal.

The most striking results came from the longitudinal arm. In a subset of 48 women with early breast cancer who gave blood before and three to six months after adjuvant chemotherapy, p16 expression rose significantly, by an average of 0.7 log2 units—an increase the authors note is equivalent to roughly 10 to 20 years of chronological aging. Yet four of the five methylation clocks—Horvath, PhenoAge, GrimAge, and the Dunedin pace—showed no significant change over the same interval. Only the Hannum clock increased, and only modestly. When the team split patients into those whose p16 rose beyond assay precision and those whose did not, none of the epigenetic clocks changed in either group, underscoring that the chemotherapy signal seen in senescence markers simply was not mirrored in the methylation-based measures.

The findings complicate the interpretation of earlier studies. Some prior work reported epigenetic age acceleration after cancer treatment: one study of breast cancer survivors found those who received chemotherapy were biologically two to three years older than controls two to three years after treatment, and a small study of 18 patients reported acceleration of roughly 3.5 to 8 years after a single anthracycline-containing cycle, though that analysis lacked paired samples. Other research found clock changes only years or decades later, or no change at all depending on regimen and follow-up timing. The new data suggest methylation clocks are not blind to treatment-related aging effects, but may respond on a different timescale or capture different biological consequences than the rapid senescence response registered by p16.

The team also explored senescence-associated secretory phenotype proteins—inflammatory molecules shed by senescent cells that have been linked to morbidity and mortality. In 20 patients treated with doxorubicin-based chemotherapy, chemotherapy-induced increases in p16 correlated with rising levels of PARC, TNFRII, ICAM1, and TNF-alpha. Intriguingly, baseline p16 showed little to no association with baseline levels of these proteins, suggesting the link is driven by the chemotherapy itself. Together with prior work showing increased p16, DNA damage, and inflammatory markers in survivors over two years, the results paint a picture in which cytotoxic chemotherapy provokes a coordinated senescence and inflammatory response that current epigenetic clocks largely miss.

The authors are careful about the limits of their analysis. The longitudinal component was exploratory and small; the cross-sectional and longitudinal cohorts differed in age and sampling protocols; p16 and methylation were measured in different biological compartments; and chemotherapy-related shifts in immune cell composition can confound whole-blood methylation measures. The three-to-six-month follow-up window may also simply be too short for clocks that evolve over years. Treatment regimens were heterogeneous, mixing anthracycline and non-anthracycline approaches, though recent long-term follow-up found persistently elevated p16 regardless of regimen.

Even so, the message is clear and potentially consequential: the most popular biomarkers of biological aging are not interchangeable. Choosing between them requires knowing which aging process—and which timescale—a study actually cares about. For the millions of breast cancer survivors living with the long-term consequences of treatment, that distinction could shape how researchers track accelerated aging, design interventions such as exercise or senolytic drugs, and ultimately judge whether a therapy that cures cancer is also quietly aging the body that carries it.

Subject of Research: Comparison of cellular senescence marker p16INK4a and DNA methylation epigenetic clocks as biomarkers of biological aging in women with early breast cancer treated with chemotherapy

Article Title: p16INK4a and DNA methylation clocks in women treated with chemotherapy for early breast cancer

Article References: p16INK4a and DNA methylation clocks in women treated with chemotherapy for early breast cancer. (n.d.). https://doi.org/10.1007/s11357-026-02521-3

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02521-3

Keywords: p16INK4a, DNA methylation clocks, biological aging, cellular senescence, breast cancer, chemotherapy, epigenetic age, GeroScience, GrimAge, PhenoAge, biomarkers of aging, cancer survivors